Amazon expanding healthcare service to 20 more cities, lands Silicon Labs, Whole Foods Market as customers Pfizer tidies up pipeline while eyeing external science to add $25B in revenue by 2030 Amgen talks long-term growth, but doubts remain for analysts, investors CooperSurgical to acquire Cook Medical's IVF, OB-GYN businesses for $875M Eli Lilly, Innovent's PD-1 in troubled waters as FDA review, oncology chief's comments portend likely rejection Anthem rolling out virtual primary care to plans in 11 states Axsome’s migraine drug finally slated for FDA inspection, but investors want to know about stalled depression therapy GN’s Jabra sends self-fitting hearing aids to market for $799 ahead of FDA over-the-counter ruling J&J pauses COVID-19 vaccine production at Dutch plant in temporary pivot to RSV shot: NYT CVS teams with Medable to expand access to clinical trials Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X Second Sight eyes buyout of Nano Precision Medical and its diabetes drug implant Featured Story | By Heather Landi Amazon has signed on three more companies for its virtual and in-person healthcare services as it continues to target the employer market. read more |
| |
|---|
|
Top Stories By Kyle LaHucik Pfizer is doing a little house cleaning of its pipeline, but not to worry. CEO Albert Bourla is expecting to bring on external science that could help reap "at least $25 billion of risk-adjusted revenues" by 2030. read more By Kevin Dunleavy Amgen is projecting compound annual growth in mid-single digits through the end of this decade. Considering the company reported 2021 revenue at $26.0 billion, that level of growth would get Amgen to roughly $35 billion in revenue in 2030, which is an ambitious goal according to analysts and investors. read more By Conor Hale Cook’s subsidiaries will continue to manufacture products for CooperSurgical during a two-year transition. read more By Angus Liu An FDA rebuff looks almost certain for Eli Lilly and partner Innovent Biologics’ PD-1 inhibitor Tyvyt as an overwhelmingly negative internal FDA review ahead of an advisory committee meeting suggests the agency is unwilling to consider a drug solely based on clinical data from China. read more By Paige Minemyer Anthem will make virtual primary care available to eligible members of its commercial health plans in 11 states, the insurer announced Tuesday. read more By Max Bayer The FDA will in fact be able to inspect Axsome’s manufacturing facility for its migraine drug by the decision date as the agency gets these crucial inspections back on track following COVID disruptions. read more By Andrea Park The Enhance Plus earbuds have been cleared by the FDA as self-fitting hearing aids. read more By Fraiser Kansteiner The news that Johnson & Johnson stopped making its pandemic vaccine at a key European plant came as a bit of a shock. Not to worry, though, the company says—the production pause was all part of the plan and should be over by next month. read more By Paige Minemyer CVS Health is teaming up with Medable to access and engage around clinical trials at select MinuteClinics, the healthcare giant announced Monday. read more By Nick Paul Taylor Ovid Therapeutics has found a potential buyer for its onetime lead program. A little more than one year after gaboxadol’s value-crushing phase 3 flop, Healx has stepped in to see whether it can write another chapter in the long, failure-strewn history of the neurological disease drug. read more By Andrea Park Clear eyes, full pockets, can’t lose. Not long after chalking up nearly $60 million in proceeds from a public offering last summer, visual prosthetic maker Second Sight Medical has set its sights on expanding into new types of medical implants. read more |
| Whitepaper: Reimagining Oncology Clinical Trials with Digital Biomarkers Health metrics enabled by wearables are a big untapped opportunity in oncology clinical trials. Yet, sponsors of cancer clinical trials have been slower to embrace digital outcome measures than their peers in other therapeutic areas. In this paper, we look at the perceived barriers to the adoption of wearables—and the major benefits that await sponsors that overcome them. Download Now. |
|
